Improving safety reporting from randomised trials.

Abstract:

:Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials is largely neglected and receives less attention compared with efficacy outcomes. An analysis of 192 randomised trials has shown that reasons for withdrawals due to toxicity were specified per study arm in only 46% of the trial reports. Adequate reporting of clinical adverse effects and laboratory-determined toxicity occurred in only 39 and 29% of the trials, respectively, even with lenient definitions of what constitutes adequate reporting. The use of standardised scales for adverse effects is a prerequisite for improved reporting on safety in randomised trials. Safety data need to be collected and analysed in a systematic fashion and active surveillance for toxicity during the conduct of a randomised trial is preferable to passive surveillance. Standardised reporting of safety data does not necessarily require extensive space to accomplish. It is essential to provide numerical data per study arm on each type of adverse effect along with a categorisation of the severity of the adverse effects with an emphasis on severe and life-threatening reactions. The severity grading must be referred to well-known standardised scales and new scales need to be carefully defined. Information on withdrawals due to toxicity is also important to report, along with the specific reasons leading to discontinuation. Tabulation of information may be helpful and rare or not previously reported adverse effects should be described in detail. The availability of newer options such as electronic publication, publication of raw databases, large database research, meta-analytic approaches, and prospective registration of clinical trials and of their databases may further improve the safety insights we can gain from randomised clinical trials.

journal_name

Drug Saf

journal_title

Drug safety

authors

Ioannidis JP,Lau J

doi

10.2165/00002018-200225020-00002

keywords:

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

77-84

issue

2

eissn

0114-5916

issn

1179-1942

pii

250202

journal_volume

25

pub_type

杂志文章,评审
  • Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.

    abstract:BACKGROUND:The availability of large-scale observational healthcare data allows for the active monitoring of safety of drugs, but research is needed to determine which statistical methods are best suited for this task. Recently, the Longitudinal Gamma Poisson Shrinker (LGPS) and Longitudinal Evaluation of Observational...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0107-x

    authors: Schuemie MJ,Madigan D,Ryan PB

    更新日期:2013-10-01 00:00:00

  • Acute fluoride toxicity. Pathophysiology and management.

    abstract::Acute intoxication with inorganic fluoride disrupts numerous physiological systems. As a potent acid it acts corrosively on the skin and mucous membranes, producing severe burns. As the most electronegative element it tightly binds many cations essential to homeostasis, producing, for example, profound hypocalcaemia a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199005020-00001

    authors: McIvor ME

    更新日期:1990-03-01 00:00:00

  • Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

    abstract:BACKGROUND:A number of published studies compare adverse event rates for drugs on the basis of reports in the US FDA Adverse Event Reporting System (AERS). While the AERS data have the advantage of timely availability and a large capture population, the database is subject to many significant biases, and lacks complete...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932020-00006

    authors: Hochberg AM,Pearson RK,O'Hara DJ,Reisinger SJ

    更新日期:2009-01-01 00:00:00

  • Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease.

    abstract::A number of affluent countries are moving to eliminate thiomersal (thimerosal), an ethylmercury preservative, from vaccines as a precautionary measure because of concerns about the potential adverse effects of mercury in infants. The WHO advocates continued use of thiomersal-containing vaccines in developing countries...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528020-00001

    authors: Bigham M,Copes R

    更新日期:2005-01-01 00:00:00

  • Drug-induced lupus erythematosus: incidence, management and prevention.

    abstract::The generation of autoantibodies and autoimmune diseases such as systemic lupus erythematosus has been associated with the use of certain drugs in humans. Early reports suggested that procainamide and hydralazine were associated with the highest risk of developing lupus, quinidine with a moderate risk and all other dr...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11588500-000000000-00000

    authors: Chang C,Gershwin ME

    更新日期:2011-05-01 00:00:00

  • Improving follow-up rates in spontaneous adverse drug reaction reporting: effectiveness of a targeted letter used by a regional centre in the UK.

    abstract:BACKGROUND:Spontaneous reports of suspected adverse drug reactions to regulatory bodies and market authorization holders are important in pharmacovigilance. Follow-up information, which can be difficult to obtain, is often required from reporters; therefore, we developed targeted follow-up letters that we hoped would m...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11318940-000000000-00000

    authors: Anton C,Cox AR,Ferner RE

    更新日期:2009-01-01 00:00:00

  • The WHO World Alliance for Patient Safety: a new challenge or an old one neglected?

    abstract::The WHO World Alliance on Patient Safety is a new, all encompassing project to improve medical care. Individual patients are the focus and all countries are encouraged to develop systems in which medical error, therapeutic accidents and failures are minimised. The potential for adverse events is present at all levels ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528050-00002

    authors: Edwards IR

    更新日期:2005-01-01 00:00:00

  • Neuropsychiatric Effects of HIV Antiviral Medications.

    abstract::The development of antiretroviral therapy (ART) has dramatically increased the lifespan of HIV patients but treatment is complicated by numerous adverse effects and toxicities. ART complications include neuropsychiatric, metabolic, gastrointestinal, cardiac, and numerous other toxicities, and clinicians often have to ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0440-y

    authors: Treisman GJ,Soudry O

    更新日期:2016-10-01 00:00:00

  • Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

    abstract:BACKGROUND:Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE:The aim of the study was to characterize ADRs reported to the WHO-ADR database, ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03262002

    authors: Aagaard L,Strandell J,Melskens L,Petersen PS,Holme Hansen E

    更新日期:2012-12-01 00:00:00

  • Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

    abstract:BACKGROUND:Potential severe liver injury is identified in clinical trials by ALT >3 × upper limits of normal (ULN) and total bilirubin >2 × ULN, and termed 'Hy's Law' by the US FDA. However, there is limited evidence or validation of these thresholds in clinical trial populations. Using liver chemistry data from clinic...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261982

    authors: Lin X,Parks D,Painter J,Hunt CM,Stirnadel-Farrant HA,Cheng J,Menius A,Lee K

    更新日期:2012-10-01 00:00:00

  • Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues.

    abstract::The article vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues, written by Tomas Bergvall. G. Niklas Norén. Marie Lindquist, was originally published Online First without open access. ...

    journal_title:Drug safety

    pub_type: 已发布勘误

    doi:10.1007/s40264-019-00803-8

    authors: Bergvall T,Norén GN,Lindquist M

    更新日期:2019-06-01 00:00:00

  • Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.

    abstract::Gastroesophageal reflux is one of the most common reasons for referrals to paediatricians or paediatric gastroenterologists. Gastric acid-buffering agents, mucosal surface barriers and gastric anti-secretory agents are the main groups of medications currently used for treating gastroesophageal reflux disease (GERD) in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0154-y

    authors: Kierkus J,Oracz G,Korczowski B,Szymanska E,Wiernicka A,Woynarowski M

    更新日期:2014-05-01 00:00:00

  • Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

    abstract:INTRODUCTION:Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00845-y

    authors: Belleudi V,Trotta F,Addis A,Ingrasciotta Y,Ientile V,Tari M,Gini R,Pastorello M,Scondotto S,Cananzi P,Traversa G,Davoli M,Trifirò G,Italian Biosimilar Network (ItaBioNet).

    更新日期:2019-12-01 00:00:00

  • Adverse effects of newer cephalosporins. An update.

    abstract::While classifications into generations according to antimicrobial activity has helped clinicians incorporate the increasing number of cephalosporins into their pharmacological repertoire, adverse effects among the different agents fail to follow similar categories. In general, cephalosporins are fairly well tolerated ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199309020-00005

    authors: Thompson JW,Jacobs RF

    更新日期:1993-08-01 00:00:00

  • Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.

    abstract:OBJECTIVE:During proton pump inhibitor (PPI) use, in clinical trials, headache is one of the most frequently reported adverse events (frequency 1.3 to 8.8%), while results of one observational study indicate that headache is the fifth most frequently reported adverse event (incidence densities 2.5 to 4.6 per 1000 patie...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200225040-00005

    authors: Claessens AA,Heerdink ER,van Eijk JT,Lamers CB,Leufkens HG

    更新日期:2002-01-01 00:00:00

  • Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

    abstract::Drug-induced QT interval prolongation is now a major concern in safety pharmacology. Regulatory authorities such as the US FDA and the European Medicines Agency require in vitro testing of all drug candidates against the potential risk for QT interval prolongation prior to clinical trials. Common in vitro methods incl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427110-00002

    authors: Meyer T,Boven KH,Günther E,Fejtl M

    更新日期:2004-01-01 00:00:00

  • Antihyperlipidaemic agents. Drug interactions of clinical significance.

    abstract::The available antihyperlipidaemic drugs are generally safe and effective, and major systemic adverse effects are uncommon. However, because of their complex mechanisms of action, careful monitoring is required to identify and correct potential drug interactions. Bile acid sequestrants are the most difficult of these a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411050-00002

    authors: Farmer JA,Gotto AM Jr

    更新日期:1994-11-01 00:00:00

  • Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

    abstract:BACKGROUND:Researchers using observational data to understand drug effects must make a number of analytic design choices that suit the characteristics of the data and the subject of the study. Review of the published literature suggests that there is a lack of consistency even when addressing the same research question...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0103-1

    authors: Stang PE,Ryan PB,Overhage JM,Schuemie MJ,Hartzema AG,Welebob E

    更新日期:2013-10-01 00:00:00

  • Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.

    abstract::Phytoestrogens, plant chemicals classified as isoflavones, coumestans and lignans, display estrogen-like activity because of their structural similarity to human estrogens and exhibit high affinity binding for the estrogen receptor beta. They are common components of food items such as grains, beans, fruits and nuts. ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124090-00003

    authors: Sirtori CR

    更新日期:2001-01-01 00:00:00

  • Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.

    abstract::Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently appr...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0773-9

    authors: Shah RR

    更新日期:2019-02-01 00:00:00

  • Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

    abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0760-1

    authors: Stein A,Franklin JL,Chia VM,Arrindell D,Kormany W,Wright J,Parson M,Amouzadeh HR,Choudhry J,Joseph G

    更新日期:2019-05-01 00:00:00

  • What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

    abstract::In the US, adverse drug reactions (ADRs) rank between the fourth to sixth leading cause of death, ahead of pneumonia and diabetes mellitus. An important reason for the high incidence of serious and fatal ADRs is that the existing drug development paradigms do not generate adequate information on the mechanistic source...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124020-00001

    authors: Ozdemir V,Shear NH,Kalow W

    更新日期:2001-01-01 00:00:00

  • Heart failure induced by non-cardiac drugs.

    abstract::Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely affect haemodynamic mechanisms in patients with an al...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629070-00003

    authors: Slørdal L,Spigset O

    更新日期:2006-01-01 00:00:00

  • Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.

    abstract:BACKGROUND:Screening large databases of spontaneous case reports of possible adverse drug reactions (ADRs) is an established method of identifying hitherto unknown adverse effects of medicinal products; however, there is a lack of consensus concerning the value of formal statistical screening procedures in guiding such...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11534410-000000000-00000

    authors: Alvarez Y,Hidalgo A,Maignen F,Slattery J

    更新日期:2010-06-01 00:00:00

  • Measles vaccination and inflammatory bowel disease: controversy laid to rest?

    abstract::The increasing incidence of Crohn's disease has lead to speculation about changes in exposures to environmental or infectious agents. Considerable attention has focused on the role of measles infection and/or vaccination in the pathogenesis of Crohn's disease and ulcerative colitis. Current evidence regarding the asso...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124130-00001

    authors: Davis RL,Bohlke K

    更新日期:2001-01-01 00:00:00

  • Performance of probabilistic method to detect duplicate individual case safety reports.

    abstract:BACKGROUND:Individual case reports of suspected harm from medicines are fundamental for signal detection in postmarketing surveillance. Their effective analysis requires reliable data and one challenge is report duplication. These are multiple unlinked records describing the same suspected adverse drug reaction (ADR) i...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0146-y

    authors: Tregunno PM,Fink DB,Fernandez-Fernandez C,Lázaro-Bengoa E,Norén GN

    更新日期:2014-04-01 00:00:00

  • Post-approval safety issues with innovative drugs: a European cohort study.

    abstract:BACKGROUND:At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0094-y

    authors: Mol PG,Arnardottir AH,Motola D,Vrijlandt PJ,Duijnhoven RG,Haaijer-Ruskamp FM,de Graeff PA,Denig P,Straus SM

    更新日期:2013-11-01 00:00:00

  • Drug therapy and the older person: role of the pharmacist.

    abstract::Older people in the UK receive a disproportionate amount of medication. They comprise 18% of the population but receive 45% of all prescription items. Not surprisingly they experience drug-related illnesses - in 1980, 1 in 10 admissions to acute geriatric units were wholly or partly due to adverse drug reactions. Drug...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819040-00001

    authors: Denham MJ,Barnett NL

    更新日期:1998-10-01 00:00:00

  • Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

    abstract::The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary prophylaxis of patients with venous thromboembolism. Even though NOACs have a better safety profile than vitamin K antagonists (VKAs), there wi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0357-x

    authors: Husted S,Verheugt FW,Comuth WJ

    更新日期:2016-01-01 00:00:00

  • Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

    abstract::Although inhaled and intranasal corticosteroids are first-line therapy for asthma and allergic rhinitis, there has recently been an increasing awareness of their propensity to produce systemic adverse effects. The availability of more potent and lipophilic corticosteroids and new chlorofluorocarbon (CFC)-free formulat...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200023010-00002

    authors: Lipworth BJ,Jackson CM

    更新日期:2000-07-01 00:00:00